Immuno-Oncology Cell Therapy Market Size, Share & Trends Analysis Report By Therapy Type (CAR-T Cells, NK & NKT Cells, TAA/TSA targeted T Cell, TCR T Cell, and Other Cell Therapies), By Indication Type, By Region, And Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Immuno-oncology Cell Therapy Market Snapshot Chapter 4. Global Immuno-oncology Cell Therapy Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis of Key Immuno-oncology Cell Therapy Industry 4.6. Industry Analysis – Porter's Five Forces Analysis 4.7. Clinical Trial/Pipeline Analysis 2021 4.8. COVID-19 Impact on Oncology Industry Chapter 5. Market Segmentation 1: Therapy Type Estimates & Trend Analysis 5.1. Therapy Type & Market Share, 2024 & 2034 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Therapy Type: 5.2.1. CAR-T Cells 5.2.2. NK & NKT Cells 5.2.3. TCR T Cells 5.2.4. TAA/TSA targeted T Cell 5.2.5. Cytokine-induced killer cells 5.2.6. Dendritic cells 5.2.7. Macrophages 5.2.8. Other Cell Therapies Chapter 6. Market Segmentation 2: Indication Type Estimates & Trend Analysis 6.1. Indication Type & Market Share, 2024 & 2034 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication Type: 6.2.1. Head & Neck Cancer 6.2.2. Lung Cancer 6.2.3. Kidney Cancer 6.2.4. Melanoma 6.2.5. Lymphoma 6.2.6. Leukemia 6.2.7. Others Chapter 7. Immuno-oncology Cell Therapy Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. North America 7.1.1. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Therapy Type, 2021-2034 7.1.2. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034 7.1.3. North America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by country, 2021-2034 7.1.3.1. U.S. 7.1.3.2. Canada 7.2. Europe 7.2.1. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034 7.2.2. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034 7.2.3. Europe Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, 2021-2034 7.2.3.1. Germany 7.2.3.2. Poland 7.2.3.3. France 7.2.3.4. Italy 7.2.3.5. Spain 7.2.3.6. UK 7.2.3.7. Rest of Europe 7.3. Asia Pacific 7.3.1. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034 7.3.2. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034 7.3.3. Asia Pacific Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, 2021-2034 7.3.3.1. China 7.3.3.2. India 7.3.3.3. Japan 7.3.3.4. Australia 7.3.3.5. Rest of Asia Pacific 7.4. Latin America 7.4.1. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, 2021-2034 7.4.2. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034 7.4.3. Latin America Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2021-2034 7.4.3.1. Brazil 7.4.3.2. Rest of Latin America 7.5. Middle East & Africa 7.5.1. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) by Therapy Type, (US$ Million) 7.5.2. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) estimates and forecasts by Indication Type, 2021-2034 7.5.3. Middle East & Africa Immuno-oncology Cell Therapy Market revenue (US$ Million) by country, (US$ Million) 2021-2034 7.5.3.1. South Africa 7.5.3.2. GCC Countries 7.5.3.3. Rest of MEA Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. Novartis 8.2.2. Juno Therapeutics 8.2.3. Agios Pharmaceutical 8.2.4. Adicet Bio, Inc. 8.2.5. Adaptimmune Therapeutics plc. 8.2.6. Atara Biotherapeutics 8.2.7. Artiva Biotherapeutics, Inc. 8.2.8. Shenzhen BinDeBio Ltd. 8.2.9. Editas Medicine 8.2.10. China Immunotech Co., Ltd. 8.2.11. CRISPR Therapeutics 8.2.12. Lion TCR 8.2.13. Autolus Limited 8.2.14. Kite Pharma 8.2.15. Bellicum Pharmaceuticals 8.2.16. bluebird bio 8.2.17. Calibr 8.2.18. Carina Biotech 8.2.19. CARsgen Therapeutics 8.2.20. Celgene Corporation 8.2.21. Cellectis 8.2.22. Cell Medica 8.2.23. Allogene Therapeutics 8.2.24. Amgen 8.2.25. Cell Design Labs 8.2.26. Celularity 8.2.27. Celyad 8.2.28. Eureka Therapeutics 8.2.29. Fate Therapeutics 8.2.30. Fortress Bio 8.2.31. Gilead Sciences 8.2.32. Immatics US Inc. 8.2.33. Immunocore 8.2.34. Sorrento Therapeutics, Inc. 8.2.35. Janssen Biotech 8.2.36. JW Therapeutics 8.2.37. Kleo Pharmaceuticals 8.2.38. Medisix Therapeutics 8.2.39. Mustang Bio 8.2.40. Medigene 8.2.41. NantKwest 8.2.42. Nanjing Legend Biotech 8.2.43. Precision Biosciences 8.2.44. Posedia Therapeutics 8.2.45. T-Cure Biosciences Inc 8.2.46. TCR2 Therapeutics 8.2.47. T-knife 8.2.48. TScan Therapeutics 8.2.49. Triumvira Immunologics USA, Inc. 8.2.50. Ziopharm 8.2.51. Zelluna Immunotherapy 8.2.52. 3T Biosciences, Inc. 8.2.53. Other Prominent Players